These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38574699)

  • 1. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.
    Luoma JB; Chwyl C; Bathje GJ; Davis AK; Lancelotta R
    J Psychoactive Drugs; 2020; 52(4):289-299. PubMed ID: 32529966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
    Soliman PS; Curley DE; Capone C; Eaton E; Haass-Koffler CL
    Psychopharmacology (Berl); 2024 Jun; 241(6):1101-1110. PubMed ID: 38683460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.
    Dos Santos RG; Osório FL; Crippa JA; Riba J; Zuardi AW; Hallak JE
    Ther Adv Psychopharmacol; 2016 Jun; 6(3):193-213. PubMed ID: 27354908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review.
    Yu Z; Burback L; Winkler O; Xu L; Dennett L; Vermetten E; Greenshaw A; Li XM; Milne M; Wang F; Cao B; Winship IR; Zhang Y; Chan AW
    Front Psychiatry; 2024; 15():1386321. PubMed ID: 38807690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
    Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
    Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.
    Basedow LA; Majić T; Hafiz NJ; Algharably EAE; Kreutz R; Riemer TG
    Sci Rep; 2024 Jun; 14(1):14782. PubMed ID: 38926480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stutterers' experiences on classic psychedelics: A preliminary self-report study.
    Jackson ES; Goldway N; Gerlach-Houck H; Gold ND
    J Fluency Disord; 2024 May; 81():106062. PubMed ID: 38833909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.
    Szafoni S; Gręblowski P; Grabowska K; Więckiewicz G
    Front Psychiatry; 2024; 15():1406888. PubMed ID: 38919636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do classic psychedelics increase the risk of seizures? A scoping review.
    Soto-Angona Ó; Fortea A; Fortea L; Martínez-Ramírez M; Santamarina E; López FJG; Knudsen GM; Ona G
    Eur Neuropsychopharmacol; 2024 Jun; 85():35-42. PubMed ID: 38917636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Uses and Adverse Effects of Psilocybin.
    Ghaznavi S; Bernardez LM; Stern TA
    Prim Care Companion CNS Disord; 2024 May; 26(3):. PubMed ID: 38815272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.
    Yaden DB; Gukasyan N; Nayak SM
    JAMA Psychiatry; 2024 Jun; 81(6):541-542. PubMed ID: 38055240
    [No Abstract]   [Full Text] [Related]  

  • 14. [Towards a Better understanding of Persisting Perceptual Disturbances following the use of Classic Psychedelics.].
    Avram M; Herwig U; Borgwardt S; Majić T
    Fortschr Neurol Psychiatr; 2024 Apr; 92(4):118-120. PubMed ID: 38636490
    [No Abstract]   [Full Text] [Related]  

  • 15. Psychedelics field looks ahead after FDA advisers' rejection.
    Kupferschmidt K
    Science; 2024 Jun; 384(6701):1158-1159. PubMed ID: 38870296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics and Older Adults: What Do They Do Compared to Younger People?
    Harvey PD
    Am J Geriatr Psychiatry; 2024 Jun; ():. PubMed ID: 38871630
    [No Abstract]   [Full Text] [Related]  

  • 17. Next-generation psychedelics: should new agents skip the trip?
    Peplow M
    Nat Biotechnol; 2024 Jun; 42(6):827-830. PubMed ID: 38831049
    [No Abstract]   [Full Text] [Related]  

  • 18. Applying the EU regulatory framework for the clinical use of psychedelics.
    Butlen-Ducuing F; Silva F; Silva I; Balabanov P; Thirstrup S
    Lancet Psychiatry; 2024 Jul; ():. PubMed ID: 38972323
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
    Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
    Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.